Patanjali Foods Hits Record Sales; FMCG Outshines Edible Oils

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorSatyam Jha|Published at:
Patanjali Foods Hits Record Sales; FMCG Outshines Edible Oils
Overview

Patanjali Foods Limited achieved record revenue of ₹10,484 crore in Q3 FY26, a 16.53% jump year-on-year, fueled by a strong 38.93% growth in its FMCG segment. While edible oils saw modest growth and low margins, the company's focus on higher-margin FMCG, staples, and biscuits is driving profitability. Management targets double-digit EBITDA margins and a balanced revenue split in the long term.

Patanjali Foods Roars to Record Revenue, FMCG Steals the Show

Patanjali Foods Limited has kicked off FY26 with a bang, reporting its highest-ever quarterly revenue of ₹10,483.71 crore for the third quarter ended March 31, 2026. This marks a significant 16.53% jump compared to the same period last year, showcasing the company's expanding reach and product appeal.

Financial Deep Dive

The company's top line surged, with revenue from operations reaching a record ₹10,483.71 crore in Q3 FY26, up 16.53% year-on-year. For the nine months of FY26, revenue also hit a new peak at ₹29,013.98 crore. However, profitability margins present a mixed picture. In Q3, EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization - a measure of operating profit) stood at ₹492.06 crore, resulting in a margin of 4.69%. This was primarily boosted by the FMCG segment, which contributed a substantial 66.33% of the total EBITDA, despite accounting for only 30.68% of revenue.

Segment Analysis

The star performer was the Fast-Moving Consumer Goods (FMCG) segment, which saw a remarkable 38.93% year-on-year revenue growth to ₹3,248 crore, and a healthy EBITDA margin of 10.88%. Within FMCG, staples like atta and rice grew by an impressive 68.70% year-on-year, and biscuits revenue rose 26.4%. Ghee also saw strong double-digit growth. In contrast, the larger Edible Oil segment, while growing 8.98% to ₹7,335.71 crore, reported a modest EBITDA margin of 2.39%. Competitors like Adani Wilmar and Marico typically operate in similar low single-digit margins for their edible oil businesses. The Oil Palm Plantation business continued to be a high-margin contributor, with a 22.47% EBITDA margin.

Strategy & Outlook

Patanjali Foods is strategically positioning itself for long-term growth, aiming for an 8-10% annual growth in its food business and targeting an 8-10% EBITDA margin for this segment. The company also plans for 15% growth in its Health and Personal Care (HPC) business. A key long-term objective is to achieve a 50-50 revenue split between edible oils and non-edible oils, driving towards overall double-digit EBITDA margins. Expansion in oil palm cultivation and strengthening distribution networks, especially in the South, are key priorities. Management anticipates favorable macro trends, including GST reforms, to further boost consumption and demand recovery. For context, established FMCG players like HUL and Nestle India typically command EBITDA margins in the 20-25% range, indicating the significant margin potential Patanjali Foods aims to capture through its FMCG expansion.

Risks & Outlook

While Patanjali Foods celebrates record revenue, the persistent low margins in its largest segment, Edible Oil (Q3 FY26: 2.39%), remain a structural challenge. The company is targeting 2-4% for this segment, aiming for the higher end. Investor focus will be on whether the company can consistently achieve its long-term goal of double-digit EBITDA margins, which heavily relies on the continued outperformance of its FMCG business and improvements in the edible oil segment. Although historical investigations into past acquisitions and corporate governance by SEBI have occurred, no new major regulatory penalties or fraud allegations are associated with this current earnings report. The company has been actively reducing its debt, with reports indicating a net debt of ₹1,779 crore and a debt-to-equity ratio of 0.29x as of early 2024, which is a positive sign for financial health.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.